Biography
Dr. Spaeth is responsible for the development of clinical content and clinical rationale for GTG products. With a focus on transposing GTG’s cutting-edge approach to disease risk modeling into effortless yet actionable genetic-integrated information for both clinicians and patients, she is a cross-functional team member. She is involved in developing and executing commercial clinical research, pilot studies and managing academic research collaborations. She has wide experience in the high complexity laboratory space from assay development to regulatory oversight of laboratory developed tests in the oncology, infectious disease and inherited disease space. Her postdoctoral training was completed at MD Anderson Cancer Center where she focused on the role of the microenvironment in tumor progression. Erika holds a Ph.D. in Biomedical Sciences from the University of Texas Health Science Center and a B.S. in Molecular Biology from the University of Connecticut.

Wellness & Aging Showcase:
Genetic Technologies Ltd
GTG are pioneers in genetic technologies, decoding the genome and unlocking its value for human health. The company is developing the next generation of integrated predictive genetic testing and assessment tools – empowering physicians and patients to proactively manage health.

Leadership in Personalised Predictive Genetics
GeneType is transforming the conversation from a one-size-fits-all model to personalised, predictive health assessment according to your individual risk. Our team, backed by over 20 years of experience, uniquely combine genetic and clinical risk models to predict risk of chronic diseases before onset.